Fibroblast growth FACTOR-23

There are 31 papers on fibroblast growth FACTOR-23 in aging research: 3 trials and 19 observational studies in people, 4 in animals, 5 reviews.

Biomarker

31 papers study it31 more mention it7 findings

MeSH

4 new papers in 30 daysSee all 62 papers on fibroblast growth FACTOR-23

“the odds ratio for prevalent frailty versus non-frailty per twofold higher FGF23 was 1.34 (95% confidence interval [CI] = 1.01-1.77)”
FGF23, Frailty, and Falls in SPRINTJournal of the American Geriatrics Society2020doi:10.1111/jgs.16895
  • Human trial3
  • Humans19
  • Animals4

Interventions

2

SGLT2 inhibitors

upin reviews1

1 study
  1. SGLT2 inhibitors increase fibroblast growth FACTOR-23 (modest increase).

    “a modest increase in phosphate, fibroblast growth factor-23 (FGF-23), and parathyroid hormone (PTH)”

    Review

    SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism

    Journal of bone metabolism

More on SGLT2 inhibitors

Pulse-based diet

no changein humans1

1 study
  1. Pulse-based diet showed no clear effect on fibroblast growth FACTOR-23 in humans.

    “However, the circulating FGF23 levels did not change in either group.”

    Human trial12 weeksn = 16

    Effects of replacing meat and fish with pulse intake on circulating fibroblast growth factor-23 levels during a 12-week dietary weight-loss intervention using the Four-Food-Group Point Method: a pilot randomized controlled study

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

More on Pulse-based diet

Effects

2

Chronic kidney disease progression

no changein humans1

1 study
  1. Fibroblast growth FACTOR-23 was not clearly linked with chronic kidney disease progression in humans (fully adjusted multivariable models).

    “Fully adjusted multivariable models of CKD progression showed no association with FGF23, vitamin D status or PTH.”

    Humansfully adjusted multivariable models

    Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3

    BMJ open

More on Chronic kidney disease progression

Mortality

no changein humans1

1 study
  1. Fibroblast growth FACTOR-23 was not clearly linked with mortality in humans after multivariable adjustment; univariable association was present.

    “FGF23 was associated with all-cause mortality in univariable but not multivariable analysis.”

    Humansafter multivariable adjustment; univariable association was present

    Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3

    BMJ open

Associations

3

Silent brain infarct

upin humans1

1 study
  1. Silent brain infarct is associated with fibroblast growth FACTOR-23 in humans (Atrial fibrillation with low embolic risk).

    “Ang-2, FGF-23, and BMP-10 were increased in patients with SBI.”

    HumansAtrial fibrillation with low embolic riskn = 70

    Association of blood-based biomarkers with radiologic markers and cognitive decline in atrial fibrillation patients

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

More on Silent brain infarct

Falls

upin humans1HR 1.99

1 study
  1. Fibroblast growth FACTOR-23 is linked with a higher risk of falls in humans (HR 1.99 per twofold higher FGF23 (95% CI 1.48-2.68); highest vs lowest quartile HR 2.32 (95% CI 1.26-4.26)).

    “the HR per twofold higher FGF23 was 1.99 (95% CI = 1.48-2.68)”

    Humansin participants with chronic kidney disease, Cox analysis adjusted for demographics, comorbidities, randomization group, antihypertensives, eGFR, mineral metabolism markers and frailtyper twofold higher FGF23n = 2,376

    FGF23, Frailty, and Falls in SPRINT

    Journal of the American Geriatrics Society

Frailty

upin humans1OR 1.34

1 study
  1. Fibroblast growth FACTOR-23 is associated with frailty in participants with chronic kidney disease, after adjustment (OR 1.34 per twofold higher FGF23 (95% CI 1.01-1.77)).

    “the odds ratio for prevalent frailty versus non-frailty per twofold higher FGF23 was 1.34 (95% confidence interval [CI] = 1.01-1.77)”

    Humansin participants with chronic kidney disease, after adjustmentper twofold higher FGF23n = 2,376

    FGF23, Frailty, and Falls in SPRINT

    Journal of the American Geriatrics Society

Funding

1 grant since 2018

National Institute on Aging$223K

Latest

Dec 2025: 2Jan 2026: 2Feb 2026: 2Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 1Sep 2026: 2Oct 2026: 1Nov 2026: 214 papers in 12 months

See all 62 papers on fibroblast growth FACTOR-23